PM
CTMX icon

Prosight Management’s CytomX Therapeutics CTMX Stock Holding History

Prosight Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-564,800
Closed -$1.8M – 45
2025
Q3 		$1.8M Sell
564,800
-2,952,313
-84% -$6.65M 0.42% 34
2025
Q2 		$7.98M Sell
3,517,113
-412,895
-11% -$666K 1.95% 17
2025
Q1 		$2.5M Buy
3,930,008
+25,008
+0.6% +$19.4K 0.82% 27
2024
Q4 		$4.02M Buy
3,905,000
+882,891
+29% +$950K 1.11% 23
2024
Q3 		$3.57M Buy
+3,022,109
New +$3.84M 0.88% 30

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Prosight Management's CTMX Position: Q4 2025 in Review

Prosight Management sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 564,800 shares — an estimated $1.8M sold.

Prosight Management first reported a position in CTMX in Q3 2024 and held it in 5 quarters. The position peaked at $7.98M in Q2 2025. 122 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

  • Prosight Management reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Prosight Management sold 564,800 CytomX Therapeutics shares in Q4 2025, an estimated $1.8M.
  • Prosight Management first reported a position in CytomX Therapeutics in Q3 2024 and held it in 5 quarters.
  • Prosight Management's CytomX Therapeutics position peaked at $7.98M in Q2 2025.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.